Share

Profile & Fundamentals

GSK Profile & Fundamentals

Name: GSK financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Company profile record

GSK plc

Common Stock · Health Care · Pharmaceuticals

Official website

Company

Company / asset: GSK plc
Security type: Common Stock
Sector: Health Care
Industry: Pharmaceuticals
HQ: 🇬🇧 United Kingdom
Head office: 79 New Oxford Street, London, United Kingdom, WC1A 1DG

Leadership & scale

Chief executive: Mr. Luke Victor Miels
CEO year born: 1974
Full-time employees: 66.8K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-09-08

Market Cap: GBP 76.3B
P/E: 15.8x
Revenue (Q2 26): GBP 8.4B
Profit (Q2 26): GBP 435.0M
Dividend Yield: 3.6%
Revenue (FY 25): GBP 32.7B
Shares in public float: 3.9B
Insider ownership: 1.75%

Reporting & identifiers

Symbol: GSK.LSE
Listing: 🇬🇧 United Kingdom | Dividend Tax: 0%
Ticker Currency: GBX
Income Statement Currency: GBP
Balance Sheet Currency: GBP
Cash Flow Currency: GBP
EPS Currency: GBP
Contract Type: SPOT
ISIN: GB00BN7SWP63
Asset ID: equity_7d4bc152-96eb-5872-be67-303e3002a0fa

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company's recent financial performance shows strong headline growth, with revenues and net income rising significantly, driven by robust sales in specialty medicines and vaccines. However, there is a clear disagreement about the quality of these earnings. Some assessments celebrate this cash-printing ability, noting that strong free cash flow easily covers dividend payments and share buybacks. Conversely, more cautious views warn that recent earnings beats were artificially boosted by one-off legal adjustments and accounting maneuvers, masking underlying weakness in the core business. Looking ahead, all agree that the upcoming patent expiration on key HIV drugs will create a major revenue hurdle. The main clash is whether new cancer treatments can ramp up fast enough to replace this lost income and maintain the company's defensive financial strength.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company currently enjoys spectacular profit margins, with gross margins around seventy-three percent, reflecting immense pricing power for its life-saving treatments. However, the future outlook for these margins is a major source of debate. Most agree that margins will face downward pressure due to government-mandated price cuts in the United States and the loss of high-margin HIV drug patents. Optimistic views believe that the company can defend its profitability by shifting patients to new long-acting injections and using artificial intelligence to lower operational costs. In contrast, skeptics argue that the current high margins have peaked and will inevitably compress as cheaper generic competitors enter the market and expensive acquisition costs drag down earnings. The consensus is that the stock's low valuation already reflects this expected margin squeeze, creating an interesting setup for patient investors.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-10.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	34,303,470,000	5,098,350,000	1,121,760,000	66.11	24.49	3.27	14.86
2017-12-31	40,449,240,000	6,319,440,000	2,052,880,000	66.54	26.42	5.08	15.62
2018-12-31	39,142,670,000	8,413,750,000	4,601,210,000	67.89	25.95	11.75	21.5
2019-12-31	44,217,740,000	7,672,670,000	6,084,950,000	67.8	23.06	13.76	17.35
2020-12-31	46,374,640,000	8,434,720,000	7,818,640,000	67.81	24	16.86	18.19
2021-12-31	33,339,600,000	6,778,350,000	5,919,750,000	66.18	21.89	17.76	20.33
2022-12-31	35,482,040,000	6,225,450,000	18,096,760,000	66.37	22.79	51	17.55
2023-12-31	38,516,560,000	5,618,480,000	6,258,560,000	70.07	23.06	16.25	14.59
2024-12-31	39,220,000,000	4,465,000,000	3,218,750,000	69.8	18.05	8.21	11.38
2025-12-31	44,100,450,000	8,039,250,000	7,716,600,000	72.54	21.95	17.5	18.23

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	13.04	Trailing four quarters
2024-12-31	21.67	Trailing four quarters
2023-12-31	12.12	Trailing four quarters
2022-12-31	3.93	Annual net income
2021-12-31	9.61	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	3,912,800,000
2018-01-01	3,982,400,000
2019-01-01	4,017,600,000
2020-01-01	4,033,600,000
2021-01-01	3,245,600,000
2022-01-01	4,091,000,000
2023-01-01	4,117,647,100
2024-01-01	4,145,000,000
2025-01-01	4,086,000,000
2026-01-01	4,062,000,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.